Practices in urethral stricture management with drug-coated balloon dilatation: an international survey

1

Male anterior urethral stricture disease has an incidence of 229–627 per 100,000 men and often recurs after conventional treatments.
2

Drug-coated balloon dilatation (DCB) is a minimally invasive alternative to traditional endoscopic treatments for urethral stricture.
3

The Optilume® device, FDA-approved in 2021, uses paclitaxel to inhibit scar re-formation and improve stricture-free intervals.
4

Clinical trials show DCB has higher patency rates and lower reintervention rates compared to standard care for urethral strictures.
5

An international survey of 102 urologists aimed to characterize real-world DCB usage patterns and inform future clinical guidelines.

World Journal Of Urology (Springer)

by Diarmuid D. Sugrue, John O’Connor, Łukasz Białek, Francesco Chierigo, Mikołaj Frankiewicz, François Xavier Madec, Behzad Abbasi, Leonidas Karapanos, Jakob Klemm, Mattia Lo Re, Juan Diego Tinajero, Jordán Scherñuk, Guglielmo Mantica, Paul Neuville, Maciej Oszczudłowski, Wesley Verla, Malte W. Vetterlein, Niall F Davis, Felix Campos-Juanatey, Elaine J. Redmond
April 7, 2026

1